Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2026-02-03 00:00:00 ET · period of report 2026-02-01 · accession 0001781549-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-03 | 2025-02-01 | ACRS | Loerop James | Chief Business Off | F - Tax | $2.48 | -16.0K | 102.8K | -13% | -$39.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-01 | F | D | 15,980 | $2.48 | 102,773 | D | — | — | (F2) This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported. This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings. |